Abstract
Biotransformation of (-)-α-santonin using Aspergillus parasiticus resulted in the production of 3,4-epoxy-α-santonin, 4,5-dihydro-α-santonin and 1,2-dihydro-α-santonin and 3 minor products and the biological activity of the transformed products was established by antibacterial & antifungal assays. 3,4-epoxy-α-santonin exhibited higher degree of antibacterial and antifungal activity. 4,5-dihydro-α-santonin showed slight increase in the activity, compared to (-)-α-Santonin. 1,2-dihydro-α-santonin is equipotent to the substrate ( (-)-α-Santonin ). This is the first report on the Biotransformation of (-)-α-Santonin by Aspergillus parasiticus and evaluation of the biological activities of the biotransformed products.
Keywords: (-)-α-santonin, biotransformation, Aspergillus parasiticus, 3, 4-epoxy-α-santonin, 4, 5-dihydro-α-santonin, 1, 2-dihydro-α-santonin, antibacterial, Cytotoxic activity, regioselectivity, stereoselectivity, anti-HIV, Spectrometry, NMR Spectrum, Antibacterial Activity, Antifungal Activity
Current Biotechnology
Title:Biotransformation of (-)-α-Santonin by Aspergillus parasiticus and Antimicrobial Efficacy of the Transformed Products
Volume: 1 Issue: 3
Author(s): Busi Siddhardha, Ramakrishna Gadupudi and Mandava Venkata Basaveswara Rao
Affiliation:
Keywords: (-)-α-santonin, biotransformation, Aspergillus parasiticus, 3, 4-epoxy-α-santonin, 4, 5-dihydro-α-santonin, 1, 2-dihydro-α-santonin, antibacterial, Cytotoxic activity, regioselectivity, stereoselectivity, anti-HIV, Spectrometry, NMR Spectrum, Antibacterial Activity, Antifungal Activity
Abstract: Biotransformation of (-)-α-santonin using Aspergillus parasiticus resulted in the production of 3,4-epoxy-α-santonin, 4,5-dihydro-α-santonin and 1,2-dihydro-α-santonin and 3 minor products and the biological activity of the transformed products was established by antibacterial & antifungal assays. 3,4-epoxy-α-santonin exhibited higher degree of antibacterial and antifungal activity. 4,5-dihydro-α-santonin showed slight increase in the activity, compared to (-)-α-Santonin. 1,2-dihydro-α-santonin is equipotent to the substrate ( (-)-α-Santonin ). This is the first report on the Biotransformation of (-)-α-Santonin by Aspergillus parasiticus and evaluation of the biological activities of the biotransformed products.
Export Options
About this article
Cite this article as:
Siddhardha Busi, Gadupudi Ramakrishna and Venkata Basaveswara Rao Mandava, Biotransformation of (-)-α-Santonin by Aspergillus parasiticus and Antimicrobial Efficacy of the Transformed Products, Current Biotechnology 2012; 1 (3) . https://dx.doi.org/10.2174/2211550111201030194
DOI https://dx.doi.org/10.2174/2211550111201030194 |
Print ISSN 2211-5501 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-551X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
LNA Antisense: A Review
Current Physical Chemistry Bioactive Flavonoids from Cornus mas L. Fruits
Mini-Reviews in Organic Chemistry Treatment of Antipsychotic-Induced Hyperprolactinemia: An Update on the Role of the Dopaminergic Receptors D2 Partial Agonist Aripiprazole
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Current Status of Epigenetics and Anticancer Drug Discovery
Anti-Cancer Agents in Medicinal Chemistry Characterization of Stem-Like Cells Directly Isolated from Freshly Resected Laryngeal Squamous Cell Carcinoma Specimens
Current Stem Cell Research & Therapy Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy
Current Cancer Drug Targets CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
Current Pharmaceutical Design The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View
Current Medicinal Chemistry Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Current Advances in Therapy for Metastatic Melanoma
Current Cancer Therapy Reviews Clinically Relevant Genetic Variations in Drug Metabolizing Enzymes
Current Drug Metabolism Serotonin and Cancer: What Is the Link?
Current Molecular Medicine NHE-1: A Promising Target for Novel Anti-cancer Therapeutics
Current Pharmaceutical Design Knockdown of Enhancer of Zeste Homolog 2 Affects mRNA Expression of Genes Involved in the Induction of Resistance to Apoptosis in MOLT-4 Cells
Anti-Cancer Agents in Medicinal Chemistry Recent Developments in CE-MS Based Metabolomics
Current Analytical Chemistry Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer
Current Vascular Pharmacology Regulation of Bcl-2 Family Proteins by Posttranslational Modifications
Current Molecular Medicine Advances in the Discovery of Anthraquinone-Based Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery “Letting the Air In” Can Set the Stage for Tumor Recurrences
Current Cancer Therapy Reviews Cisplatin Is a DNA-Damaging Antitumour Compound Triggering Multifactorial Biochemical Responses in Cancer Cells: Importance of Apoptotic Pathways
Current Medicinal Chemistry - Anti-Cancer Agents